Reid Robison

Reid is co-founder at Cedar Psychiatry, and serves as Medical Director of Center for Change, a leading Eating Disorder program. He is currently the coordinating investigator for the MAPS-sponsored study MDMA-assisted psychotherapy study of eating disorders. As an early adopter and researcher of Ketamine in psychiatry, Reid led a pivotal ketamine study for TRMDD by Janssen, leading up to the company's recent FDA-approval of Spravato. To date, Reid has guided thousands of ketamine therapy journeys and hundreds of Spravato dosing sessions. As a social entrepreneur, Reid has built a number of purpose-driven companies including Tute Genomics. Reid is an adjunct professor and founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad.